137 related articles for article (PubMed ID: 16184606)
41. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
[TBL] [Abstract][Full Text] [Related]
42. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Dec; 50(6):373-80. PubMed ID: 11761463
[TBL] [Abstract][Full Text] [Related]
43. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Sep; 50(3):373-80. PubMed ID: 11558794
[TBL] [Abstract][Full Text] [Related]
44. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages.
Varani K; Bachoud-Lévi AC; Mariotti C; Tarditi A; Abbracchio MP; Gasperi V; Borea PA; Dolbeau G; Gellera C; Solari A; Rosser A; Naji J; Handley O; Maccarrone M; Peschanski M; DiDonato S; Cattaneo E
Neurobiol Dis; 2007 Jul; 27(1):36-43. PubMed ID: 17512749
[TBL] [Abstract][Full Text] [Related]
45. The molecular genetics of Huntington's disease.
Goldberg YP; Telenius H; Hayden MR
Curr Opin Neurol; 1994 Aug; 7(4):325-32. PubMed ID: 7952241
[TBL] [Abstract][Full Text] [Related]
46. Preliminary analysis of Huntington's Disease in South Korea.
Shin CW; Choi YJ; Kim M; Jeon BS
J Huntingtons Dis; 2013; 2(1):83-7. PubMed ID: 25063431
[TBL] [Abstract][Full Text] [Related]
47. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset.
Andresen JM; Gayán J; Djoussé L; Roberts S; Brocklebank D; Cherny SS; ; ; Cardon LR; Gusella JF; MacDonald ME; Myers RH; Housman DE; Wexler NS
Ann Hum Genet; 2007 May; 71(Pt 3):295-301. PubMed ID: 17181545
[TBL] [Abstract][Full Text] [Related]
48. A(2A) adenosine receptor binding parameters in platelets from patients affected by pathological gambling.
Martini C; Daniele S; Picchetti M; Panighini A; Carlini M; Trincavelli ML; Cesari D; Da Pozzo E; Golia F; Dell'Osso L
Neuropsychobiology; 2011; 63(3):154-9. PubMed ID: 21228607
[TBL] [Abstract][Full Text] [Related]
49. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
[TBL] [Abstract][Full Text] [Related]
50. The p. R151C Polymorphism in MC1R Gene Modifies the Age of Onset in Spanish Huntington's Disease Patients.
Tell-Marti G; Puig-Butille JA; Gimenez-Xavier P; Segu-Roig A; Potrony M; Badenas C; Alvarez V; Millán JM; Trujillo-Tiebas MJ; Ramos-Arroyo MA; Milà M; Puig S
Mol Neurobiol; 2017 Jul; 54(5):3906-3910. PubMed ID: 27924526
[TBL] [Abstract][Full Text] [Related]
51. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.
Wright GEB; Collins JA; Kay C; McDonald C; Dolzhenko E; Xia Q; Bečanović K; Drögemöller BI; Semaka A; Nguyen CM; Trost B; Richards F; Bijlsma EK; Squitieri F; Ross CJD; Scherer SW; Eberle MA; Yuen RKC; Hayden MR
Am J Hum Genet; 2019 Jun; 104(6):1116-1126. PubMed ID: 31104771
[TBL] [Abstract][Full Text] [Related]
52. Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.
Matusch A; Saft C; Elmenhorst D; Kraus PH; Gold R; Hartung HP; Bauer A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1210-20. PubMed ID: 24566949
[TBL] [Abstract][Full Text] [Related]
53. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease.
Nazé P; Vuillaume I; Destée A; Pasquier F; Sablonnière B
Neurosci Lett; 2002 Aug; 328(1):1-4. PubMed ID: 12123845
[TBL] [Abstract][Full Text] [Related]
54. A patient with early onset Huntington disease and severe cerebellar atrophy.
Sakazume S; Yoshinari S; Oguma E; Utsuno E; Ishii T; Narumi Y; Shiihara T; Ohashi H
Am J Med Genet A; 2009 Feb; 149A(4):598-601. PubMed ID: 19253382
[TBL] [Abstract][Full Text] [Related]
55. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
56. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent.
Telenius H; Kremer HP; Theilmann J; Andrew SE; Almqvist E; Anvret M; Greenberg C; Greenberg J; Lucotte G; Squitieri F
Hum Mol Genet; 1993 Oct; 2(10):1535-40. PubMed ID: 8268906
[TBL] [Abstract][Full Text] [Related]
57. Nonparametric modeling and analysis of association between Huntington's disease onset and CAG repeats.
Ma Y; Wang Y
Stat Med; 2014 Apr; 33(8):1369-82. PubMed ID: 24027120
[TBL] [Abstract][Full Text] [Related]
58. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
59. Adenosine receptors and Huntington's disease.
Lee CF; Chern Y
Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
[TBL] [Abstract][Full Text] [Related]
60. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing.
Ramos-Arroyo MA; Moreno S; Valiente A
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):337-42. PubMed ID: 15716522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
